Eirgen Pharma Ltd.

Global CDMO Partner Specializing in High-Potency Oral Solid Dose & Softgel Manufacturing

At Eirgen Pharma, we specialize in developing and manufacturing high-quality high-potency Oral Solid Dose (OSD) products for human and companion animal health. As a leading CDMO, we offer end-to-end services spanning pharmaceutical development, clinical and commercial manufacturing, and integrated packaging - enabling efficient, reliable market entry.

​

CPHI Frankfurt 2025

Meet with Eirgen Pharma at CPHI 2025
Join us to explore flexible, high-quality CDMO solutions for oral solid dose & softgel development, clinical supply, commercial manufacturing, and packaging. Whether you're seeking a partner for high-potency or non-potent compounds, our expert team is ready to help you accelerate your product to market. Book a meeting to discover how our new 500M+ unit capacity can support your pipeline.

  • 30m

  • 1

DCAT Week 2026

Meet with Eirgen Pharma at DCAT Week 2026
Join us to explore flexible, high-quality CDMO solutions for oral solid dose & softgel development, clinical supply, commercial manufacturing, and packaging. Whether you're seeking a partner for high-potency or non-potent compounds, our expert team is ready to help you accelerate your product to market. Book a meeting to discover how our new 750M+ unit capacity can support your pipeline.

  • 30m

  • 1

Eirgen Pharma Ltd. | Cal.com